Deals, Insight journal - Dealtalk, M&A

Valeant bid re-focusses pharma M&A interest

Posted on 07 April 2011

Tags: ,

Valeant Pharmaceuticals' $5.7 billion bid for Cephalon may spawn a series of copycat deals, Reuters reports...

How so? Because it defies the common belief that products nearing the end of their patent lives--such as Cepahlon's Provigil wakefulness drug--aren't worth the trouble.

Read the latest analysis on the Valeant bid at Reuters

 

Print Friendly, PDF & Email

Leave a Reply